Survival Outcomes for Men over 80 Years Undergoing Transrectal Ultrasound-Guided Prostate Biopsy: A Prospective Analysis DOI Open Access
D.A. Alghamdi,

Neil Kernohan,

Chunhui Li

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(23), P. 3995 - 3995

Published: Nov. 28, 2024

Introduction: Prostate cancer is the second most prevalent among elderly males in Western countries. TRUS biopsy remains a standard diagnosing approach for prostate but poses notable risks, particularly older men, including complications such as sepsis, acute retention, and rectal bleeding, which can lead to substantial morbidity mortality. This study aimed evaluate cancer-specific survival outcomes men aged over 80 years whether there any advantage procedure. Methods: Between January 2005 December 2015, we studied of 200 patients (median age, 82 years) with elevated prostate-specific antigen (PSA) levels (>4.0 ng/mL) and/or abnormal digital examination (DRE) who underwent biopsy. Each participant was followed up until death using an electronic system unique identifier defined geographical area. Cancer-specific overall analyses were carried out utilising SPSS, while R Project employed construct two nomograms duration predict risk post-biopsy. All statistical tests two-tailed, significance set at p < 0.05. Results: Amongst participants, only 24 alive end follow-up 91 years). The PSA ranged from 4.88 102.7 ng/mL. Log-rank Breslow indicated that higher levels, development metastases, ISUP grade group 8–10 associated shorter times. Age, co-morbid conditions, tumour type incorporated into nomogram due their clinical significance. Patients <81 had lower mortality risk, those >88 faced risks. Complications increased risks both cancerous benign cases, metastasis significantly heightened likelihood death. However, conditions did not influence probability. Conclusions: Our findings underscore age (specifically above), high Gleason score, metastasis, are predictive poorer following

Language: Английский

Advanced prostate cancer diagnosed by bone metastasis biopsy immediately after initial negative prostate biopsy: a case report and literature review DOI Creative Commons

Mingwen Liu,

Zhifei Xie,

Wen Tang

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: May 10, 2024

Prostate cancer (PCa) is a prevalent male malignancy that originates in the epithelial cells of prostate. In terms incidence and mortality malignant tumors men, PCa ranks second fifth globally first third among men Europe United States, respectively. These figures have gradually increased recent years. The primary modalities used to diagnose include prostate-specific antigen (PSA), multiparametric magnetic resonance imaging (mpMRI), prostate puncture biopsy. Among these techniques, biopsy considered gold standard for diagnosis PCa; however, this method carries potential missed diagnoses. preoperative evaluation patient study suggested advanced PCa. However, initial was inconsistent with diagnosis, instead waiting repeat primary, we performed rib metastasis, which later diagnosed as

Language: Английский

Citations

0
Integration of PSAd and multiparametric MRI to forecast biopsy outcomes in biopsy-naïve patients with PSA 4~20 ng/ml DOI Creative Commons
Lei Ren, Yanling Chen, Zixiong Liu

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: July 4, 2024

Introduction This study aims to investigate whether the transrectal ultrasound-guided combined biopsy (CB) improves detection rates of prostate cancer (PCa) and clinically significant PCa (csPCa) in biopsy-naïve patients. We also aimed compare Prostate Imaging Reporting Data System (PI-RADS v2.1) score, ADC values, PSA density (PSAd) predicting csPCa by biopsy. Methods retrospective single-center included 389 patients with level 4~20 ng/ml, whom 197 underwent prebiopsy mpMRI prostate. The mpMRI-based scores v2.1 values) clinical parameters were collected evaluated logistic regression analyses. Multivariable models based on developed analyses forecast outcomes CB ROC curves measured AUC calibration plots, DCA performed assess multivariable models. Results can detect more compared TRUSB (32.0% vs. 53%). Spearman correlation revealed that Gleason significantly correlated PI-RADS values. multivariate confirmed 4, 5, volume important predictors csPCa. PI-RADS+ADC+PSAd (PAP) model had highest AUCs 0.913 for ng/ml. When risk threshold PAP was greater than or equal 0.10, 51% could avoid an unnecessary biopsy, only 5% missed. Conclusion have a high CDR A PSAd provide reference clinicians forecasting ng/ml make comprehensive assessment during decision-making

Language: Английский

Citations

0
Oncologic and Functional Outcomes following Robot Assisted Radical Prostatectomy: 15-year experience in a Latin American referral center DOI
Agustín Romeo,

Pablo Martínez,

Martin Compagnucci

et al.

Surgical Oncology, Journal Year: 2024, Volume and Issue: 57, P. 102138 - 102138

Published: Sept. 12, 2024

Language: Английский

Citations

0
Editorial for Special Topics: Imaging-Based Diagnosis for Prostate Cancer—State of the Art DOI Creative Commons

Rulon Mayer,

Peter L. Choyke, Charles B. Simone

et al.

Diagnostics, Journal Year: 2024, Volume and Issue: 14(18), P. 2016 - 2016

Published: Sept. 12, 2024

This Special Topics Issue, "Imaging-based Diagnosis of Prostate Cancer-State the Art",

Language: Английский

Citations

0
Interpretable Machine Learning for Prostate Biopsy: Cohort Study DOI

Jindong Dai,

Chen Zhu,

Xiang Tu

et al.

Published: Jan. 1, 2024

Language: Английский

Citations

0
Development and validation of a nomogram prediction model for clinically significant prostate cancer combined with PI-RADS V2.1, MRI quantitative parameters and clinical indicators: a two-center study DOI Creative Commons
Yunhui Chen,

Long Yan,

Jiang Xianmei

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Nov. 22, 2024

Objective To develop and validate a multi-index nomogram prediction model for clinically significant prostate cancer(CSPCa) by combining the PI-RADS V2.1, quantitative magnetic resonance imaging (MRI) parameters clinical indicators. Methods A total of 1740 patients (75% in derivation cohort 25% internal validation cohort) 342 (the external were retrospectively included MRI follow-up database First Affiliated Hospital Kunming Medical University between January 2015 April 2021,and Gejiu People’s 2020 December 2022.Important predictors CSPCa MRI-related parameters, PSA-derived indicators, such as age, screened. The Net Reclassification Improvement Index(NRI),Integrated Discrimination Index(IDI), decision curve analysis (DCA) calculated to compare performances different models. Receiver operating characteristic(ROC) curves calibration used analyze diagnostic effects. Results AUC value, best cut-off specificity, sensitivity accuracy 1(PI-RADS + PSAD) 0.935, 0.304, 0.861, 0.895 0.872, respectively. values cohorts 1 0.956 0.955, 2(PI-RADS +PSAD ADCmean) 0.939, 0.401, 0.895, 0.853 0.882, 2 0.940 0.960,respectively. After adding ADCmean model, NRI(categorical), NRI(continuous) IDI 0.0154, 0.3498 0.0222, There was no difference predicted probability actual (p&gt; 0.05). Conclusion Models had reliable, efficient visual predictive value CSPCa. is an important indicator.

Language: Английский

Citations

0
Survival Outcomes for Men over 80 Years Undergoing Transrectal Ultrasound-Guided Prostate Biopsy: A Prospective Analysis DOI Open Access
D.A. Alghamdi,

Neil Kernohan,

Chunhui Li

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(23), P. 3995 - 3995

Published: Nov. 28, 2024

Introduction: Prostate cancer is the second most prevalent among elderly males in Western countries. TRUS biopsy remains a standard diagnosing approach for prostate but poses notable risks, particularly older men, including complications such as sepsis, acute retention, and rectal bleeding, which can lead to substantial morbidity mortality. This study aimed evaluate cancer-specific survival outcomes men aged over 80 years whether there any advantage procedure. Methods: Between January 2005 December 2015, we studied of 200 patients (median age, 82 years) with elevated prostate-specific antigen (PSA) levels (>4.0 ng/mL) and/or abnormal digital examination (DRE) who underwent biopsy. Each participant was followed up until death using an electronic system unique identifier defined geographical area. Cancer-specific overall analyses were carried out utilising SPSS, while R Project employed construct two nomograms duration predict risk post-biopsy. All statistical tests two-tailed, significance set at p < 0.05. Results: Amongst participants, only 24 alive end follow-up 91 years). The PSA ranged from 4.88 102.7 ng/mL. Log-rank Breslow indicated that higher levels, development metastases, ISUP grade group 8–10 associated shorter times. Age, co-morbid conditions, tumour type incorporated into nomogram due their clinical significance. Patients <81 had lower mortality risk, those >88 faced risks. Complications increased risks both cancerous benign cases, metastasis significantly heightened likelihood death. However, conditions did not influence probability. Conclusions: Our findings underscore age (specifically above), high Gleason score, metastasis, are predictive poorer following

Language: Английский

Citations

0